This site is intended for healthcare professionals

Libtayo filed in Japan to treat patients with cervical cancer.

Read time: 1 mins
Published:23rd Mar 2022

Sanofi has filed a new drug application for its PD-1 inhibitor cemiplimab (Libtayo) in Japan on March 18 as a monotherapy for the treatment of patients with cervical cancer whose disease progressed on or after chemotherapy.

The submission is based on data from a global PIII study, which enrolled roughly 600 patients with relapsed/metastatic cervical cancer previously treated with chemotherapy. In the study, cemiplimab demonstrated a 31% reduction in the risk of deaths versus chemotherapy.

Condition: Cervical Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights